{'fraction_non_alphanumeric': 0.022381378692927483, 'fraction_numerical': 0.017009847806624886, 'mean_word_length': 5.734939759036145, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prognosis and Therapeutic Biomarker in the Management of Gastric Adenocarcinoma in Brazzaville

Introduction: Gastric cancer is predominantly represented by adenocarcinoma, which is the most common histological type. The latter develops from the gastric epithelium and remains a global public health problem. The aim of the study was to assess the overexpression of the Her2 biomarker of gastric adenocarcinoma in Brazzaville.
Materials and Methods: Samples of gastric carcinomatous tissues (paraffin blocks) were analyzed by the manual immunohistochemistry technique for the evaluation of the Her2 biomarker. Samples were collected retrospectively between January 2008 and December 2018.
Results: during this period, 52 samples were analyzed. The immunohistochemistry results show that the Her2 protein positivity rate in adenocarcinoma cases was 9.6%.
Conclusion: The results obtained during this preliminary study confirm the presence of the Her2 biomarker in 9.6% of gastric adenocarcinoma cases, which is consistent with the data in the literature.

Key words: Her2, Gastric adenocarcinoma, Immunohistochemistry.